Arvinas delivered a strong fourth quarter in 2025, primarily driven by a substantial increase in collaboration revenue. The company reported a net loss of $45.3 million, a significant improvement from the $70.1 million net loss in the same period last year. Research and development expenses remained a major investment, reflecting ongoing clinical programs.

Arvinas posted a net loss of $35.1 million for Q3 2025, reflecting decreased collaboration revenue and reduced operating expenses as the company transitions development responsibilities to partners.

Arvinas posted a net loss of $35.1 million for Q3 2025, reflecting decreased collaboration revenue and reduced operating expenses as the company transitions development responsibilities to partners.

Arvinas reported a net income of $82.9 million for the first quarter of 2025, a significant improvement from a net loss of $69.4 million in the same period last year, driven by a substantial increase in revenue to $188.8 million. The company also announced positive Phase 3 trial results for vepdegestrant and strategic reprioritization of its development plans, including workforce reductions to extend cash runway.

Arvinas reported its Q4 and full year 2024 financial results, highlighting progress across its pipeline, including the upcoming topline data from the VERITAC-2 Phase 3 trial and the initiation of a Phase 1 trial with ARV-102 in patients with Parkinson's disease. The company's cash, cash equivalents, and marketable securities are expected to fund operations into 2027.

Arvinas reported revenue of $102.4 million for the quarter ended September 30, 2024. Cash, cash equivalents and marketable securities were $1,121.6 million as of September 30, 2024. The company is on track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25.

Arvinas made significant progress across its portfolio in Q2 2024, highlighted by the upcoming VERITAC-2 Phase 3 trial readout and strategic transaction with Novartis, receiving $150 million upfront and potentially $1.01 billion in milestones and royalties.

Arvinas reported a decrease in revenue for the quarter ended December 31, 2023, with a significant adjustment due to a change in contract estimate related to the Pfizer ARV-471 Collaboration Agreement. The company highlighted progress in multiple clinical trials, including those for vepdegestrant and ARV-766, and anticipates several upcoming milestones.

Arvinas reported Q3 2023 financial results with revenues of $34.6 million and a net loss of $64.0 million. The company is advancing its PROTAC protein degraders, including vepdegestrant and ARV-766, through clinical trials and expects to file IND applications for new compounds by year-end 2023. Cash, cash equivalents, and marketable securities totaled $1,004.0 million, sufficient to fund operations into 2026.

Arvinas reported Q2 2023 financial results with revenues of $54.5 million and a net loss of $66.6 million. The company's cash, cash equivalents, and marketable securities were $1,044.3 million as of June 30, 2023, which is expected to fund operations into 2026. Clinical trials for vepdegestrant and bavdegalutamide are ongoing, with potential Phase 3 data read-out expected in the second half of 2024.

Arvinas reported revenues of $32.5 million and a net loss of $81.9 million for the quarter ended March 31, 2023. The company's cash, cash equivalents, restricted cash and marketable securities were $1,129.0 million as of March 31, 2023, which is expected to fund operations into 2026.

Arvinas reported a net loss of $82.9 million for the quarter ended December 31, 2022, compared to a net loss of $52.9 million for the same period in 2021. Revenue for the quarter was $38.0 million, an increase from $28.7 million in the prior year. The company's cash, cash equivalents, restricted cash and marketable securities were $1,210.8 million as of December 31, 2022.

Arvinas reported revenues of $30.3 million and a net loss of $66.2 million for the third quarter of 2022. The company is on track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer.

Arvinas reported financial results for the second quarter ended June 30, 2022. The company is on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year and has a clear development pathway for bavdegalutamide in molecularly defined metastatic castration-resistant prostate cancer. The company is preparing to initiate its Phase 2 trial with ARV-766 by end of year.

Arvinas reported first quarter 2022 financial results, highlighting a productive quarter as the company prepares to initiate three planned pivotal clinical studies in the second half of 2022 for ARV-471 and bavdegalutamide.

Arvinas reported a net loss of $53.0 million for the quarter ended December 31, 2021, compared to a net loss of $41.5 million for the same period in 2020. Revenue for the quarter was $26.3 million, primarily driven by the ARV-471 Collaboration Agreement with Pfizer.

Arvinas reported Q3 2021 financial results, including revenues of $9.3 million and a net loss of $46.8 million. The company highlighted its collaboration with Pfizer and advancements in its clinical-stage programs, particularly ARV-471 and ARV-110.

Arvinas reported a net loss of $50.3 million for the second quarter of 2021, compared to a net loss of $25.2 million for the same period in 2020. Revenue was $5.5 million, slightly less than the $5.7 million reported in the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $605.1 million as of June 30, 2021.

Arvinas reported a net loss of $41.0 million for the quarter ended March 31, 2021, compared to a net loss of $21.7 million for the quarter ended March 31, 2020. Revenues were $5.5 million for the quarter ended March 31, 2021, compared to $6.2 million for the quarter ended March 31, 2020. As of March 31, 2021, cash, cash equivalents and marketable securities were $651.3 million.

Arvinas reported positive efficacy signals in both clinical-stage programs and closed an underwritten public offering of common stock, receiving net proceeds of $431.9 million. The company's cash, cash equivalents, and marketable securities are expected to fund operations into 2024.

Arvinas reported a net loss of $30.8 million for the third quarter of 2020, compared to a net loss of $17.7 million for the same period in 2019. Research and development expenses increased to $30.0 million, and general and administrative expenses were $9.3 million. Cash, cash equivalents, and marketable securities totaled $248.6 million as of September 30, 2020.

Arvinas reported its Q2 2020 financial results, highlighted by revenue of $5.7 million and a net loss of $25.2 million. The company's cash, cash equivalents, and marketable securities totaled $242.7 million as of June 30, 2020, expected to fund operations into 2022.

Arvinas reported revenue of $6.2 million and a net loss of $21.7 million for the first quarter ended March 31, 2020. The company's cash, cash equivalents, and marketable securities were $262.8 million as of March 31, 2020, which is expected to fund operations into 2022.

Arvinas reported a net loss of $21.0 million for the fourth quarter of 2019, compared to a net loss of $16.1 million for the same period in 2018. Revenue for the quarter was $4.9 million, up from $3.4 million in the prior year. The company's cash, cash equivalents, and marketable securities totaled $280.9 million as of December 31, 2019.